Stay updated on IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for a Phase II study of IMMU-132 alone or with carboplatin for triple-negative breast cancer, including its study details, eligibility criteria, and withdrawn status.
    Difference
    36%
    Check dated 2026-11-08T13:34:14.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0, while the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T14:45:56.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The study record view now displays a 403 Forbidden message with a Home link, while a notice about NIH website changes appears above the page.
    Difference
    2%
    Check dated 2026-10-25T13:48:02.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T14:19:00.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-11T13:57:54.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the previous study record content with an access-denied message. This indicates that the study's details are no longer publicly accessible through the current page.
    Difference
    16%
    Check dated 2026-09-20T08:48:03.000Z thumbnail image

Stay in the know with updates to IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page.